Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs

Yufeng Xiao, Jia Wang, Lisa Y. Zhao, Xinyi Chen, Guangrong Zheng, Xuan Zhang and Daiqing Liao

Chem. Commun., 2020, 56, 9866
DOI: 10.1039/D0CC03243C

Chemically induced degradation of epigenetic targets

Md Kabir, Xufen Yu, H. Ümit Kaniskan and Jian Jin

Chem. Soc. Rev., 2023, 52, 4313
DOI: 10.1039/D3CS00100H

Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)

Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, Yuri Takada, Tetsuya Iida, Makoto Oba, Yukihiro Itoh and Takayoshi Suzuki

Chem. Commun., 2022, 58, 4635
DOI: 10.1039/D2CC00272H

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras

Jasmine M. Cross, Megan E. Coulson, Joshua P. Smalley, Wiktoria A. Pytel, Ozair Ismail, Justin S. Trory, Shaun M. Cowley and James T. Hodgkinson

RSC Med. Chem., 2022, 13, 1634
DOI: 10.1039/D2MD00199C

PROTAC chemical probes for histone deacetylase enzymes

Urvashi Patel, Joshua P. Smalley and James T. Hodgkinson

RSC Chem. Biol., 2023, 4, 623
DOI: 10.1039/D3CB00105A

Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3

Aline R. Pavan, Joshua P. Smalley, Urvashi Patel, Wiktoria A. Pytel, Jean Leandro dos Santos, Shaun M. Cowley, John W. R. Schwabe and James T. Hodgkinson

Chem. Commun., 2024, 60, 13879
DOI: 10.1039/D4CC05138F

Synthetic and structure–activity studies of SP2577 and TCP towards LSD1 targeting PROTACs

Megan E. Coulson, James K. S. Norris, Sean A. Smith, Joshua P. Smalley, John W. R. Schwabe, Shaun M. Cowley and James T. Hodgkinson

RSC Med. Chem., 2025, 16, 4952
DOI: 10.1039/D5MD00420A

Developments of CRBN-based PROTACs as potential therapeutic agents

Chao Wang, Yujing Zhang, Yudong Wu and Dongming Xing

European Journal of Medicinal Chemistry, 2021, 225, 113749
DOI: 10.1016/j.ejmech.2021.113749

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention

Dusan Ruzic, Nemanja Djoković, Tatjana Srdić-Rajić, Cesar Echeverria, Katarina Nikolic and Juan F. Santibanez

Pharmaceutics, 2022, 14, 209
DOI: 10.3390/pharmaceutics14010209

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death

Abdullah Alraddadi, Joshua P. Smalley, Wael Alzahrani, Anes Saleh, Fares Al‐Mansour, Buwei He, Thong H. Cao, Sandrine Jayne, Martin Dyer, James T. Hodgkinson, Donald J. L. Jones, Shaun M. Cowley and Salvador Macip

eJHaem, 2025, 6
DOI: 10.1002/jha2.70127

Proteolysis Targeting Chimeras (PROTACs): An Innovative Strategy for Targeted Protein Degradation and Disease Treatment

Jun Xia, James K.S. Norris, May-Li MacKinnon and Sam Butterworth

IJDDP, 2024, 100015
DOI: 10.53941/ijddp.2024.100015

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, Liyan cheng, Zhimin Zhang, Jian Wang and Zhengrong Shen

European Journal of Medicinal Chemistry, 2021, 210, 112981
DOI: 10.1016/j.ejmech.2020.112981

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Hany S. Ibrahim, Menglu Guo, Sebatian Hilscher, Frank Erdmann, Matthias Schmidt, Mike Schutkowski, Chunquan Sheng and Wolfgang Sippl

Bioorganic Chemistry, 2024, 153, 107887
DOI: 10.1016/j.bioorg.2024.107887

Development of Human Carbonic Anhydrase II Heterobifunctional Degraders

Conor B. O’Herin, Yuta W. Moriuchi, Troy A. Bemis, Alysia J. Kohlbrand, Michael D. Burkart and Seth M. Cohen

J. Med. Chem., 2023, 66, 2789
DOI: 10.1021/acs.jmedchem.2c01843

Targeted protein degradation: A promise for undruggable proteins

Kusal T.G. Samarasinghe and Craig M. Crews

Cell Chemical Biology, 2021, 28, 934
DOI: 10.1016/j.chembiol.2021.04.011

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Joshua P. Smalley, Shaun M. Cowley and James T. Hodgkinson

Molecules, 2020, 25, 4394
DOI: 10.3390/molecules25194394

Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression

Chengheng Liao, Siying Lyu, Rebecca L. Johnson, Tiantian Shang, Xiaoyu Wang, Nina Gildor, Shina Li, Noelle S. Williams, Lindsey I. James, Lianxin Hu and Qing Zhang

Cell Chemical Biology, 2026
DOI: 10.1016/j.chembiol.2026.03.013

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300

Raghu Vannam, Jan Sayilgan, Samuel Ojeda, Barbara Karakyriakou, Eileen Hu, Johannes Kreuzer, Robert Morris, Xcanda Ixchel Herrera Lopez, Sumit Rai, Wilhelm Haas, Michael Lawrence and Christopher J. Ott

Cell Chemical Biology, 2021, 28, 503
DOI: 10.1016/j.chembiol.2020.12.004

Recent advances in dual PROTACs degrader strategies for disease treatment

Jianyu Liu, Yanzhuo Liu, Jiao Tang, Qianyuan Gong, Guoyi Yan, Hengrui Fan, Xueping Zhang and Chunlan Pu

European Journal of Medicinal Chemistry, 2024, 279, 116901
DOI: 10.1016/j.ejmech.2024.116901

Strategies for designing proteolysis targeting chimaeras (PROTACs)

Shipeng He, Guoqiang Dong, Junfei Cheng, Ying Wu and Chunquan Sheng

Medicinal Research Reviews, 2022, 42, 1280
DOI: 10.1002/med.21877

Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC

Jiangying Cao, Wei Zhao, Chunlong Zhao, Qian Liu, Shunda Li, Guozhen Zhang, C. James Chou and Yingjie Zhang

Molecules, 2020, 25, 4991
DOI: 10.3390/molecules25214991

Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects

Jinxiao Ru, Yuxi Wang, Zijia Li, Jiaxing Wang, Changyu Ren and Jifa Zhang

European Journal of Medicinal Chemistry, 2023, 261, 115800
DOI: 10.1016/j.ejmech.2023.115800

MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3

Joshua P. Smalley, Shaun M. Cowley and James T. Hodgkinson

ACS Med. Chem. Lett., 2024, 15, 93
DOI: 10.1021/acsmedchemlett.3c00449

Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)

Daniela Tomaselli, Nicola Mautone, Antonello Mai and Dante Rotili

European Journal of Medicinal Chemistry, 2020, 207, 112750
DOI: 10.1016/j.ejmech.2020.112750

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen and Yong Peng

Mol Cancer, 2022, 21
DOI: 10.1186/s12943-021-01434-3

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy

Jing Liu, Yunhua Peng, Hiroyuki Inuzuka and Wenyi Wei

Seminars in Cancer Biology, 2022, 86, 269
DOI: 10.1016/j.semcancer.2022.07.001

Developments of PROTACs technology in immune-related diseases

Chao Wang, Yujing Zhang, Junwen Deng, Bing Liang and Dongming Xing

European Journal of Medicinal Chemistry, 2023, 249, 115127
DOI: 10.1016/j.ejmech.2023.115127

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

Jing Liu, Yunhua Peng and Wenyi Wei

Front. Cell Dev. Biol., 2021, 9
DOI: 10.3389/fcell.2021.678077

Designing HDAC-PROTACs: Lessons Learned So Far

Fabian Fischer, Leandro A Alves Avelar, Laoise Murray and Thomas Kurz

Future Med. Chem., 2022, 14, 143
DOI: 10.4155/fmc-2021-0206

The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes

Wiktoria A. Pytel, Urvashi Patel, Joshua P. Smalley, Christopher J. Millard, Edward A. Brown, Aline R. Pavan, Siyu Wang, Jay H. Kalin, Jean Leandro dos Santos, Philip A. Cole, James T. Hodgkinson and John W. R. Schwabe

J. Am. Chem. Soc., 2025, 147, 36044
DOI: 10.1021/jacs.5c08929

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Yingxin Lu, Danwen Sun, Donghuai Xiao, Yingying Shao, Mingbo Su, Yubo Zhou, Jia Li, Shulei Zhu and Wei Lu

Molecules, 2021, 26, 7241
DOI: 10.3390/molecules26237241

Current trends in development of HDAC-based chemotherapeutics

Narges Cheshmazar, Maryam Hamzeh-Mivehroud, Hojjatollah Nozad Charoudeh, Salar Hemmati, Jelena Melesina and Siavoush Dastmalchi

Life Sciences, 2022, 308, 120946
DOI: 10.1016/j.lfs.2022.120946

An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)

Yi-Min Liu and Jing-Ping Liou

Expert Opinion on Therapeutic Patents, 2023, 33, 349
DOI: 10.1080/13543776.2023.2219393

Current strategies for the design of PROTAC linkers: a critical review

Robert I. Troup, Charlene Fallan and Matthias G. J. Baud

Exploration of Targeted Anti-tumor Therapy, 2020, 1
DOI: 10.37349/etat.2020.00018

30th Annual GP2A Medicinal Chemistry Conference

Niamh M. O’Boyle, Jean-Jacques Helesbeux, Mary J. Meegan, Astrid Sasse, Elizabeth O’Shaughnessy, Alina Qaisar, Aoife Clancy, Florence McCarthy and Pascal Marchand

Pharmaceuticals, 2023, 16, 432
DOI: 10.3390/ph16030432

Targeting histone deacetylases for cancer therapy: Trends and challenges

Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang and Xuben Hou

Acta Pharmaceutica Sinica B, 2023, 13, 2425
DOI: 10.1016/j.apsb.2023.02.007

Exploring the landscape of post-translational modification in drug discovery

Yuhao Cao, Tianyi Yu, Ziang Zhu, Yuanjiao Zhang, Shanliang Sun, Nianguang Li, Chunyan Gu and Ye Yang

Pharmacology & Therapeutics, 2025, 265, 108749
DOI: 10.1016/j.pharmthera.2024.108749

PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies

Ambati Himaja, Debojyoti Halder, Suvankar Banerjee, Swati Biswas, Nilanjan Adhikari and Balaram Ghosh

ChemMedChem, 2025, 20
DOI: 10.1002/cmdc.202500203

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation

Laura Márquez-Cantudo, Ana Ramos, Claire Coderch and Beatriz de Pascual-Teresa

Molecules, 2021, 26, 5606
DOI: 10.3390/molecules26185606

Cereblon: promise and challenges for combating human diseases

Hyoung Kyu Kim, Jung Eun Seol, Sang Woo Ahn, Seungje Jeon, Chul-Seung Park and Jin Han

Pflugers Arch - Eur J Physiol, 2021, 473, 1695
DOI: 10.1007/s00424-021-02624-0

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology

Xuyang Zhao, Yifan Chen, Huang Su and Liqin Zhang

Interdisciplinary Medicine, 2023, 1
DOI: 10.1002/INMD.20230004

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders

Nisha Setia, Haider Thaer Abdulhameed Almuqdadi and Mohammad Abid

European Journal of Medicinal Chemistry, 2024, 265, 116041
DOI: 10.1016/j.ejmech.2023.116041

PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators

Sunny Periyasamy, Thyla Jarrett, Joe Truong and Rachid Skouta

Journal of Enzyme Inhibition and Medicinal Chemistry, 2026, 41
DOI: 10.1080/14756366.2026.2636394

Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues

Marta Pichlak, Tomasz Sobierajski, Katarzyna M. Błażewska and Edyta Gendaszewska-Darmach

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38
DOI: 10.1080/14756366.2023.2254012

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

Terence C. S. Ho, Alex H. Y. Chan and A. Ganesan

J. Med. Chem., 2020, 63, 12460
DOI: 10.1021/acs.jmedchem.0c00830

Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders

Sarah F. Giardina, Elena Valdambrini, Pradeep K. Singh, Manny D. Bacolod, Ganesh Babu-Karunakaran, Michael Peel, J. David Warren and Francis Barany

J. Med. Chem., 2024, 67, 5473
DOI: 10.1021/acs.jmedchem.3c02097

Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8

Zhiqiang Sun, Bulian Deng, Zichao Yang, Ruiyao Mai, Junli Huang, Zeli Ma, Ting Chen and Jianjun Chen

European Journal of Medicinal Chemistry, 2022, 239, 114544
DOI: 10.1016/j.ejmech.2022.114544

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing and Chao Wang

Materials Today Advances, 2025, 28, 100644
DOI: 10.1016/j.mtadv.2025.100644

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Xiaopeng Peng, Zhihao Hu, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Weiming Chen, Wen Hou, Kui Cheng, Huichang Bi, Wanyi Pan and Jianjun Chen

Acta Pharmaceutica Sinica B, 2024, 14, 533
DOI: 10.1016/j.apsb.2023.09.003

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)

Laura Sinatra, Jan J. Bandolik, Martin Roatsch, Melf Sönnichsen, Clara T. Schoeder, Alexandra Hamacher, Andrea Schöler, Arndt Borkhardt, Jens Meiler, Sanil Bhatia, Matthias U. Kassack and Finn K. Hansen

Angew Chem Int Ed, 2020, 59, 22494
DOI: 10.1002/anie.202006725

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells

Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, Li-Ying Lin, Karen J. Bowman, John W. R. Schwabe, Shaun M. Cowley and James T. Hodgkinson

J. Med. Chem., 2022, 65, 5642
DOI: 10.1021/acs.jmedchem.1c02179

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Dhanusha A. Nalawansha and Craig M. Crews

Cell Chemical Biology, 2020, 27, 998
DOI: 10.1016/j.chembiol.2020.07.020

Medicinal chemistry approaches to the discovery and development of p300/CBP inhibitors for cancer therapy

Huan Wang, Dandan Song, Miao Miao, Simeng Wu, Jiao Wang, Zhe Huang and Hao Ding

European Journal of Medicinal Chemistry, 2025, 297, 117959
DOI: 10.1016/j.ejmech.2025.117959

Advances in the Design and Development of PROTAC-mediated HDAC Degradation

Daniel Alencar Rodrigues, Andrew Roe, Darren Griffith and Tríona Ní Chonghaile

CTMC, 2022, 22, 408
DOI: 10.2174/1568026621666211015092047

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

Md Sadique Hussain, Liming Zhang, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Yumna Khan, Vikas Jakhmola, Ali Hanbashi, Wedad Mawkili and Gyas Khan

Future Medicinal Chemistry, 2025, 17, 1725
DOI: 10.1080/17568919.2025.2533113

Small-Molecule PROTACs for Cancer Immunotherapy

Zefan Liu, Yajun Zhang, Yucheng Xiang and Xin Kang

Molecules, 2022, 27, 5439
DOI: 10.3390/molecules27175439

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Yonghan He, Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu, Yaxia Yuan, Robert Hromas, Mingjiang Xu, Guangrong Zheng and Daohong Zhou

J Hematol Oncol, 2020, 13
DOI: 10.1186/s13045-020-00924-z

Construction of polydopamine nanomedicine for dual inhibition and degradation of histone deacetylases in cancer cells

Xin Ding, Hu Miao, Chenwei Duan, Shunchao Zhao, Jin Zhang, Yi Liu, Juan Xu, Ming Sun and Yanjun Hu

International Journal of Biological Macromolecules, 2025, 313, 144340
DOI: 10.1016/j.ijbiomac.2025.144340

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)

India M. Baker, Joshua P. Smalley, Khadija A. Sabat, James T. Hodgkinson and Shaun M. Cowley

Biochemistry, 2023, 62, 645
DOI: 10.1021/acs.biochem.2c00288

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Jie Peng, Hongyan Liu, Yujing Liu, Jingqian Liu, Qianlong Zhao, Wenjia Liu, Haoqian Niu, Haoyu Xue, Jie Sun and Jingde Wu

Bioorganic Chemistry, 2024, 153, 107818
DOI: 10.1016/j.bioorg.2024.107818

Therapeutic targeting of chromatin: status and opportunities

Marton Siklos and Stefan Kubicek

The FEBS Journal, 2022, 289, 1276
DOI: 10.1111/febs.15966

Chemo-proteomics exploration of HDAC degradability by small molecule degraders

Yuan Xiong, Katherine A. Donovan, Nicholas A. Eleuteri, Nadia Kirmani, Hong Yue, Anthony Razov, Noah M. Krupnick, Radosław P. Nowak and Eric S. Fischer

Cell Chemical Biology, 2021, 28, 1514
DOI: 10.1016/j.chembiol.2021.07.002

A bibliometric analysis of PROTAC from 2001 to 2021

Deping Li, Dongmin Yu, Yan Li and Renze Yang

European Journal of Medicinal Chemistry, 2022, 244, 114838
DOI: 10.1016/j.ejmech.2022.114838

Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity

Laura Sinatra, Jing Yang, Julian Schliehe-Diecks, Niklas Dienstbier, Melina Vogt, Philip Gebing, Luisa M. Bachmann, Melf Sönnichsen, Thomas Lenz, Kai Stühler, Andrea Schöler, Arndt Borkhardt, Sanil Bhatia and Finn K. Hansen

J. Med. Chem., 2022, 65, 16860
DOI: 10.1021/acs.jmedchem.2c01659

Chromatin Regulatory Targets for Anticancer Therapeutics

Paige A. Barta, Trever R. Carter and Michael A. Erb

Chem. Rev., 2025, 125, 9679
DOI: 10.1021/acs.chemrev.5c00231

Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer

Yu Chen, Jiahong Su, Sha Li, Feier Chen, Yan Zhang, Xingyue Wang, Yinping Zhang, Xiang Wang, Zijun Yuan, Siqi Ren, Xinyu He, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Shuai Deng, Jing Shen and Zhangang Xiao

CMC, 2025, 32, 8530
DOI: 10.2174/0109298673332285241104091609

HDAC Inhibitors: Innovative Strategies for Their Design and Applications

Mateusz Daśko, Beatriz de Pascual-Teresa, Irene Ortín and Ana Ramos

Molecules, 2022, 27, 715
DOI: 10.3390/molecules27030715

Tackling drug resistance in ovarian cancer with epigenetic targeted drugs

Lin Zhao, Hongjie Guo, Xi Chen, Wenxin Zhang, Qiaojun He, Ling Ding and Bo Yang

European Journal of Pharmacology, 2022, 927, 175071
DOI: 10.1016/j.ejphar.2022.175071

Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader

Felix Feller, Heiko Weber, Martina Miranda, Irina Honin, Maria Hanl and Finn K. Hansen

ChemMedChem, 2025, 20
DOI: 10.1002/cmdc.202500035

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Hong‐Yi Zhao, Minhang Xin and San‐Qi Zhang

Drug Development Research, 2023, 84, 337
DOI: 10.1002/ddr.22026

Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)

Xingrui He, Zi Hui, Li Xu, Renren Bai, Yuan Gao, Zongcheng Wang, Tian Xie and Xiang-Yang Ye

European Journal of Medicinal Chemistry, 2022, 227, 113946
DOI: 10.1016/j.ejmech.2021.113946

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

Ming He, Chaoguo Cao, Zhihao Ni, Yongbo Liu, Peilu Song, Shuang Hao, Yuna He, Xiuyun Sun and Yu Rao

Sig Transduct Target Ther, 2022, 7
DOI: 10.1038/s41392-022-00999-9

Overview of class I HDAC modulators: Inhibitors and degraders

Ziqian Huang, Limei Zeng, Binbin Cheng and Deping Li

European Journal of Medicinal Chemistry, 2024, 276, 116696
DOI: 10.1016/j.ejmech.2024.116696

Synthesis of a HDAC inhibitor–nanogold probe for cryo-EM visualization in class I HDAC co-repressor complexes

Wiktoria A Pytel, John W R Schwabe and James T Hodgkinson

Beilstein J. Org. Chem., 2026, 22, 480
DOI: 10.3762/bjoc.22.35

Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6

Yufeng Xiao and Xuan Zhang

Future Drug. Discov., 2020, 2
DOI: 10.4155/fdd-2020-0023

PROTACs in gastrointestinal cancers

Yu Chen, Qingfan Yang, Jinrun Xu, Liyao Tang, Yan Zhang, Fukuan Du, Yueshui Zhao, Xu Wu, Mingxing Li, Jing Shen, Ruilin Ding, Hongying Cao, Wanping Li, Xiaobing Li, Meijuan Chen, Zhigui Wu, Chi Hin Cho, Yu Du, Qinglian Wen and Zhangang Xiao

Molecular Therapy - Oncolytics, 2022, 27, 204
DOI: 10.1016/j.omto.2022.10.012

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Yufeng Xiao, Seth Hale, Nikee Awasthee, Chengcheng Meng, Xuan Zhang, Yi Liu, Haocheng Ding, Zhiguang Huo, Dongwen Lv, Weizhou Zhang, Mei He, Guangrong Zheng and Daiqing Liao

Cell Chemical Biology, 2023, 30, 1421
DOI: 10.1016/j.chembiol.2023.07.010

Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities

Yuxiang Zhang, David Remillard, Ugoma Onubogu, Barbara Karakyriakou, Joshua N. Asiaban, Anissa R. Ramos, Kirsten Bowland, Timothy R. Bishop, Paige A. Barta, Stephanie Nance, Adam D. Durbin, Christopher J. Ott, Michalina Janiszewska, Benjamin F. Cravatt and Michael A. Erb

Nat Struct Mol Biol, 2023, 30, 1160
DOI: 10.1038/s41594-023-01041-4

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance

Sarah F. Giardina, Elena Valdambrini, J. David Warren and Francis Barany

CCDT, 2021, 21, 306
DOI: 10.2174/1568009621666210203110857

Advances and Opportunities in Epigenetic Chemical Biology

Jenna N. Beyer, Nicole R. Raniszewski and George M. Burslem

ChemBioChem, 2021, 22, 17
DOI: 10.1002/cbic.202000459

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs

Laura Sinatra, Jan J. Bandolik, Martin Roatsch, Melf Sönnichsen, Clara T. Schoeder, Alexandra Hamacher, Andrea Schöler, Arndt Borkhardt, Jens Meiler, Sanil Bhatia, Matthias U. Kassack and Finn K. Hansen

Angewandte Chemie, 2020, 132, 22681
DOI: 10.1002/ange.202006725

PROTACs targeting epigenetic proteins

Chao Zhang, Yuna He, Xiuyun Sun, Wenyi Wei, Yanlong Liu and Yu Rao

Acta Materia Medica, 2023, 2
DOI: 10.15212/AMM-2023-0039

HDAC-targeting epigenetic modulators for cancer immunotherapy

Binbin Cheng, Wei Pan, Yao Xiao, Zongbao Ding, Yingxing Zhou, Xiaoting Fei, Jin Liu, Zhenhong Su, Xiaopeng Peng and Jianjun Chen

European Journal of Medicinal Chemistry, 2024, 265, 116129
DOI: 10.1016/j.ejmech.2024.116129

Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning

Li Xie, Lei Xie and Anna R Panchenko

PLoS Comput Biol, 2023, 19, e1010974
DOI: 10.1371/journal.pcbi.1010974

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

Natsuko Macabuag, William Esmieu, Perla Breccia, Rebecca Jarvis, Wesley Blackaby, Ovadia Lazari, Liudvikas Urbonas, Maria Eznarriaga, Rachel Williams, Annelieke Strijbosch, Rhea Van de Bospoort, Kim Matthews, Cole Clissold, Tammy Ladduwahetty, Huw Vater, Patrick Heaphy, Douglas G. Stafford, Hong-Jun Wang, John E. Mangette, George McAllister, Vahri Beaumont, Thomas F. Vogt, Hilary A. Wilkinson, Elizabeth M. Doherty and Celia Dominguez

J. Med. Chem., 2022, 65, 12445
DOI: 10.1021/acs.jmedchem.2c01149

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Chao Wang, Yujing Zhang, Jie Wang and Dongming Xing

European Journal of Medicinal Chemistry, 2022, 227, 113906
DOI: 10.1016/j.ejmech.2021.113906

Discovery of highly potent HDAC8 PROTACs with anti-tumor activity

Chunlong Zhao, Deng Chen, Fengzhi Suo, Rita Setroikromo, Wim J. Quax and Frank J. Dekker

Bioorganic Chemistry, 2023, 136, 106546
DOI: 10.1016/j.bioorg.2023.106546

The application of PROTAC in HDAC

Shaoting Chen, Yuxiang Zheng, Benji Liang, Yudong Yin, Jian Yao, Quande Wang, Yanghan Liu and Nouri Neamati

European Journal of Medicinal Chemistry, 2023, 260, 115746
DOI: 10.1016/j.ejmech.2023.115746

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner and Thomas Büch

Cancers, 2021, 13, 634
DOI: 10.3390/cancers13040634

Annual review of PROTAC degraders as anticancer agents in 2022

Xiao Wang, Zhao-Long Qin, Na Li, Mei-Qi Jia, Qiu-Ge Liu, Yi-Ru Bai, Jian Song, Shuo Yuan and Sai-Yang Zhang

European Journal of Medicinal Chemistry, 2024, 267, 116166
DOI: 10.1016/j.ejmech.2024.116166

PROTAC: targeted drug strategy. Principles and limitations

O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, F. A. Zenov, E. V. Manasova, A. A. Shtil and A. V. Kurkin

Russ Chem Bull, 2022, 71, 2310
DOI: 10.1007/s11172-022-3659-z

An overview of PROTACs: a promising drug discovery paradigm

Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong and Yongmei Xie

Mol Biomed, 2022, 3
DOI: 10.1186/s43556-022-00112-0